Inhibiting NLRP3 Inflammasome Activation by CY-09 Helps to Restore Cerebral Glucose Metabolism in 3×Tg-AD Mice

Bibliographic Details
Title: Inhibiting NLRP3 Inflammasome Activation by CY-09 Helps to Restore Cerebral Glucose Metabolism in 3×Tg-AD Mice
Authors: Shuangxue Han, Zhijun He, Xia Hu, Xiaoqian Li, Kaixin Zheng, Yingying Huang, Peng Xiao, Qingguo Xie, Jiazuan Ni, Qiong Liu
Source: Antioxidants, Vol 12, Iss 3, p 722 (2023)
Publisher Information: MDPI AG, 2023.
Publication Year: 2023
Collection: LCC:Therapeutics. Pharmacology
Subject Terms: Alzheimer’s disease, glucose metabolism, NLRP3 inflammasome, insulin resistance, oxidative stress, CY-09, Therapeutics. Pharmacology, RM1-950
More Details: The reduction of the cerebral glucose metabolism is closely related to the activation of the NOD-like receptor protein 3 (NLRP3) inflammasome in Alzheimer’s disease (AD); however, its underlying mechanism remains unclear. In this paper, 18F-flurodeoxyglucose positron emission tomography was used to trace cerebral glucose metabolism in vivo, along with Western blotting and immunofluorescence assays to examine the expression and distribution of associated proteins. Glucose and insulin tolerance tests were carried out to detect insulin resistance, and the Morris water maze was used to test the spatial learning and memory ability of the mice. The results show increased NLRP3 inflammasome activation, elevated insulin resistance, and decreased glucose metabolism in 3×Tg-AD mice. Inhibiting NLRP3 inflammasome activation using CY-09, a specific inhibitor for NLRP3, may restore cerebral glucose metabolism by increasing the expression and distribution of glucose transporters and enzymes and attenuating insulin resistance in AD mice. Moreover, CY-09 helps to improve AD pathology and relieve cognitive impairment in these mice. Although CY-09 has no significant effect on ferroptosis, it can effectively reduce fatty acid synthesis and lipid peroxidation. These findings provide new evidence for NLRP3 inflammasome as a therapeutic target for AD, suggesting that CY-09 may be a potential drug for the treatment of this disease.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2076-3921
Relation: https://www.mdpi.com/2076-3921/12/3/722; https://doaj.org/toc/2076-3921
DOI: 10.3390/antiox12030722
Access URL: https://doaj.org/article/1a0c54f39917419f8e3c0d3215af5a44
Accession Number: edsdoj.1a0c54f39917419f8e3c0d3215af5a44
Database: Directory of Open Access Journals
More Details
ISSN:20763921
DOI:10.3390/antiox12030722
Published in:Antioxidants
Language:English